Spectral Diagnostics Inc. (OTCMKTS:EDTXF – Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 13,085 shares, a decline of 41.5% from the August 15th total of 22,385 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 18,209 shares, the days-to-cover ratio is currently 0.7 days.
Spectral Diagnostics Price Performance
Shares of Spectral Diagnostics stock opened at $0.91 on Wednesday. The business’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $0.98. The firm has a market cap of $266.24 million, a PE ratio of -9.06 and a beta of 0.16. Spectral Diagnostics has a 52 week low of $0.81 and a 52 week high of $1.24.
About Spectral Diagnostics
Spectral Diagnostics, now known as Spectral Medical Inc, is a Canadian medical-device and biotechnology company focused on products for the diagnosis and treatment of sepsis and septic shock. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and can contribute to severe systemic inflammation.
Spectral’s primary diagnostic product is the Endotoxin Activity Assay (EAA), a blood test designed to measure a patient’s endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
Featured Articles
- Five stocks we like better than Spectral Diagnostics
- Homebuilders Are Down for the Year, Is Wall Street in Denial?
- Turning Trash to Cash: A $129M Bet on Waste
- Marex Stock Doubles on Record Profits, But Can the Rally Continue?
- 2 “Cheap for a Reason” Airline Stocks That May Be Worth the Risk
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
